โ Scribed by Judith E. Woll
No coin nor oath required. For personal study only.
A "snapshot" survey of physician coverage for evaluation and supervision of therapeutic apheresis procedures shows significant variation in current clinical practice between 39 blood center-and 41 non-blood center-based programs. Whereas 56% of blood center-based programs usually require physician's "in person" evaluation of the patient, 86% of non-blood center programs do ( P < .005). Similarly, non-blood center-based programs were more likely to have physicians on the premises to supervise first and subsequent procedures and to bill separately for medical coverage.
These differences were unrelated to location of the procedure (in hospital, blood bank, outpatient department, or other), the size of the program, or any information provided on adverse reactions.
๐ SIMILAR VOLUMES
Although the vast majority of patients with IgA nephropathy run a benign renal course, IgA nephropathy is sometimes associated with RPGN. Removal of circulating IgA-containing immune complexes may prevent worsening of renal function in such patients with IgA
The development and future trend of therapeutic apheresis in Europe was analyzed. Demographic data on its distribution were collected with the help of the marketing departments of four commercial companies. The differences in application in European countries were examined and compared with North Am
Therapeutic apheresis in pediatrics requires selected modifications due to the child's smaller size, blood volume, and developmental age. Red blood cell priming is used to prevent dilution of the child's hematocrit from the normal saline prime. Continuous flow cell separators maintain isovolemia. Di